Glymidine sodium
Glymidine sodium (INN, also known as glycodiazine; trade name Gondafon) is a sulfonamide antidiabetic drug, structurally related to the sulfonylureas. It was first reported in 1964, and introduced to clinical use in Europe in the mid to late 1960s.[1]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | High |
Protein binding | 90% |
Elimination half-life | 3.8 hours |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.842 |
Chemical and physical data | |
Formula | C13H15N3O4S |
Molar mass | 309.34 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
References
- "Glymidine". British Medical Journal. 2 (5555): 817. June 1967. doi:10.1136/bmj.2.5555.817. PMC 1843097. PMID 6029147.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.